← Back to patent-cliff list
Fluzoparib
Tier C — Watch / tradeFluzoparib
-
Originator
2020
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：PARP1, PARP-2
Brand：AiRuiYi
Indications (approved)：Breast cancer, Peritoneal cancer, Ovarian cancer, Fallopian tube cancer
Regional status
US
-
EU
-
China
Approved
2020-12-11
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Fluzoparib?
Approved indications include: Breast cancer, Peritoneal cancer, Ovarian cancer, Fallopian tube cancer.
When does the Fluzoparib patent expire?
No public expiry year is available for Fluzoparib yet; this page updates once verified.
How do I get a quote for Fluzoparib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27